Suppression of post-surgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3. セルメディシン株式会社が紹介する自家がんワクチン療法に関する記事や、論文をご覧いただけます。

Clin Case Rep. 2015 Jun;3(6):444-7.

Issei Kawashima ¹, Yuri Kawashima ², Yasuo Matsuoka ¹, Kiyotaka Fujise ³, Hideki Sakai ⁴, Mari Takahashi ⁵, Toshiaki Yoshikawa ⁵, Tetsuya Nakatsura ⁵, Takeshi Ishihara ⁶ & Tadao Ohno ⁶

^1. Hikarigaoka Clinic Green-town Hikarigaoka 4-10-10, Kashiwa, Chiba, 277-0062, Japan. 
^2. Hikarigaoka Clinic Green-town Hikarigaoka 4-10-10, Kashiwa, Chiba, 277-0062, Japan ; National Cheng Kung University 1 University Road, Tainan 701, Taiwan. 
^3. Fujise Internal Medicine Clinic Minamikashiwachuo 1-6, Kashiwa, Chiba, 277-0075, Japan. 
^4. Kashiwa Municipal Hospital Fuse1-3, Kashiwa, Chiba, 277-0825, Japan. 
^5. Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Kashiwa, Chiba, 277-8577, Japan. 
^6. Cell-Medicine, Inc. Sengen 2-1-6, Tsukuba Science City, Ibaraki, 305-0047, Japan.

Key Clinical Message: 

Autologous formalin-fixed tumor vaccine (AFTV) suppressed re-recurrence for more than 32 months of multiple-recurrent hepatocellular carcinoma based on hepatitis C virus-induced liver cirrhosis in a case with previous recurrence interval, 51-, 28-, 12-, and 4-months. We detected glypican-3-specific cytotoxic T lymphocytes in the peripheral blood at 12 months after AFTV.